Welcome to the POTP board, the DPP-IV company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: rareearth42	10/4/2006 9:16:53 PM
	of 90

pther.com Has the phase 2 results in NSCLC. There was one complete response in a squamous cell tumor and one in an adenocarcinoma. Don't stop at that poster, however. Also read the others, particularly the phase 2 results in melanoma and fludarabine and rituxan-refractory CLL. Here's the link: pther.com I think the POTP strategy will be to give a lot to a NSCLC partner in exchange for higher current payments and milestones, but to retain ownership of the other indications for which they would then be able to fund studies, then file sNDAs for each as data became available. There is also likely to be off label use for many other tumors, as soon as Talabostat gets a compendium listing. We're waiting for that partnership announcement......... RE42

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next